KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
Medical - Instruments & Supplies
Market Cap$1.26B
5Y Perf.-13.6%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
KMTS vs DBVT vs MDT vs ALKS
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.+193.1%
MDT
Medtronic plc
Medical - Devices
Market Cap$99.94B
5Y Perf.-13.2%
ALKS
Alkermes plc
Biotechnology
Market Cap$5.90B
5Y Perf.+7.2%
KMTS vs DBVT vs MDT vs ALKS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KMTS | DBVT | MDT | ALKS |
|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Biotechnology | Medical - Devices | Biotechnology |
| Market Cap | $1.26B | $1712.35T | $99.94B | $5.90B |
| Revenue (TTM) | $84M | $0.00 | $35.48B | $1.56B |
| Net Income (TTM) | $-145M | $-168M | $4.61B | $153M |
| Gross Margin | 48.8% | — | 61.9% | 65.4% |
| Operating Margin | -171.5% | — | 17.9% | 12.3% |
| Forward P/E | — | — | 14.1x | 24.8x |
| Total Debt | $44M | $22M | $28.52B | $70M |
| Cash & Equiv. | $238M | $194M | $2.22B | $1.12B |
KMTS vs DBVT vs MDT vs ALKS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KMTS
DBVT
MDT
ALKS
| Stock | Mar 25 | May 26 | Return |
|---|---|---|---|
| KESTRA MEDICAL TECH… (KMTS) | 100 | 86.4 | -13.6% |
| DBV Technologies S.… (DBVT) | 100 | 293.1 | +193.1% |
| Medtronic plc (MDT) | 100 | 86.8 | -13.2% |
| Alkermes plc (ALKS) | 100 | 107.2 | +7.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KMTS vs DBVT vs MDT vs ALKS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MDT leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. KESTRA MEDICAL TECHNOLOGIES, LTD. is the stronger pick specifically for growth and revenue expansion. DBVT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
The Growth Leader
KMTS is the #2 pick in this set and the best alternative if growth is your priority.
- 115.1% revenue growth vs DBVT's -100.0%
Best for: growth
DBVT
DBV Technologies S.A.
The Momentum Pick
DBVT is the clearest fit if your priority is momentum.
- +110.4% vs MDT's -2.8%
Best for: momentum
MDT
Medtronic plc
The Income Pick
MDT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Rev growth 3.6%, EPS growth 30.8%, 3Y rev CAGR 1.9%
- 26.5% 10Y total return vs KMTS's -1.5%
- Beta 0.47, yield 3.6%, current ratio 1.85x
Best for: income & stability and growth exposure
ALKS
Alkermes plc
The Defensive Pick
ALKS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
Best for: sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KMTS | 115.1% revenue growth vs DBVT's -100.0% |
| Value | MDT | Better valuation composite |
| Quality / Margins | MDT | 13.0% margin vs KMTS's -173.0% |
| Stability / Safety | MDT | Beta 0.47 vs KMTS's 1.87 |
| Dividends | MDT | 3.6% yield, 36-year raise streak, vs KMTS's 0.2%, (2 stocks pay no dividend) |
| Momentum (1Y) | DBVT | +110.4% vs MDT's -2.8% |
| Efficiency (ROA) | MDT | 175.8% ROA vs DBVT's -89.0% |
KMTS vs DBVT vs MDT vs ALKS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
FY 2025
KMTS vs DBVT vs MDT vs ALKS — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMDTLAGGINGKMTS
Who Leads Where
MDT leads in 2 of 6 categories
ALKS leads 1 • DBVT leads 1 • KMTS leads 0 • 2 tied
Explore the data ↓KMTSKESTRA MEDICAL TECHNO…
0leads
ALKSAlkermes plc
1leads
DBVTDBV Technologies S.A.
1leads
MDTMedtronic plc
2leads
6 Total Categories
CATEGORYLEADERvs DBVTvs ALKSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
MDT2/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ALKS6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
MDT2/2
Income & Cash Flow (Last 12 Months)
Evenly matched — MDT and ALKS each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT and DBVT operate at a comparable scale, with $35.5B and $0 in trailing revenue. MDT is the more profitable business, keeping 13.0% of every revenue dollar as net income compared to KMTS's -173.0%. On growth, KMTS holds the edge at +62.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | KMTSKESTRA MEDICAL TE… | DBVTDBV Technologies … | MDTMedtronic plc | ALKSAlkermes plc |
|---|---|---|---|---|
| RevenueTrailing 12 months | $84M | $0 | $35.5B | $1.6B |
| EBITDAEarnings before interest/tax | -$142M | -$112M | $9.4B | $212M |
| Net IncomeAfter-tax profit | -$145M | -$168M | $4.6B | $153M |
| Free Cash FlowCash after capex | -$120M | -$151M | $5.4B | $392M |
| Gross MarginGross profit ÷ Revenue | +48.8% | — | +61.9% | +65.4% |
| Operating MarginEBIT ÷ Revenue | -171.5% | — | +17.9% | +12.3% |
| Net MarginNet income ÷ Revenue | -173.0% | — | +13.0% | +9.8% |
| FCF MarginFCF ÷ Revenue | -143.3% | — | +15.2% | +25.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +62.7% | — | +8.8% | +28.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -22.0% | +91.5% | -11.9% | -4.1% |
Evenly matched — MDT and ALKS each lead in 2 of 6 comparable metrics.
Valuation Metrics
MDT leads this category, winning 2 of 5 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, MDT trades at a 13% valuation discount to ALKS's 24.8x P/E. On an enterprise value basis, MDT's 14.3x EV/EBITDA is more attractive than ALKS's 17.3x.
| Metric | KMTSKESTRA MEDICAL TE… | DBVTDBV Technologies … | MDTMedtronic plc | ALKSAlkermes plc |
|---|---|---|---|---|
| Market CapShares × price | $1.3B | $1712.35T | $99.9B | $5.9B |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $1712.35T | $126.2B | $4.9B |
| Trailing P/EPrice ÷ TTM EPS | -4.19x | -0.76x | 21.60x | 24.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 14.13x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 36.00x | — |
| EV / EBITDAEnterprise value multiple | — | — | 14.32x | 17.25x |
| Price / SalesMarket cap ÷ Revenue | 20.99x | — | 2.98x | 4.00x |
| Price / BookPrice ÷ Book value/share | 5.19x | 0.66x | 2.08x | 3.28x |
| Price / FCFMarket cap ÷ FCF | — | — | 19.28x | 12.28x |
MDT leads this category, winning 2 of 5 comparable metrics.
Profitability & Efficiency
ALKS leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
MDT delivers a 9.4% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to MDT's 0.59x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | KMTSKESTRA MEDICAL TE… | DBVTDBV Technologies … | MDTMedtronic plc | ALKSAlkermes plc |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -68.8% | -130.2% | +9.4% | +8.8% |
| ROA (TTM)Return on assets | -48.8% | -89.0% | +175.8% | +5.4% |
| ROICReturn on invested capital | -6.6% | — | +6.0% | +18.9% |
| ROCEReturn on capital employed | -78.6% | -145.7% | +7.5% | +14.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.22x | 0.13x | 0.59x | 0.04x |
| Net DebtTotal debt minus cash | -$193M | -$172M | $26.3B | -$1.0B |
| Cash & Equiv.Liquid assets | $238M | $194M | $2.2B | $1.1B |
| Total DebtShort + long-term debt | $44M | $22M | $28.5B | $70M |
| Interest CoverageEBIT ÷ Interest expense | -13.93x | -189.82x | 9.08x | 32.30x |
ALKS leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs MDT's -2.8%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs MDT's -1.4% — a key indicator of consistent wealth creation.
| Metric | KMTSKESTRA MEDICAL TE… | DBVTDBV Technologies … | MDTMedtronic plc | ALKSAlkermes plc |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -11.8% | +4.9% | -18.1% | +25.3% |
| 1-Year ReturnPast 12 months | -1.5% | +110.4% | -2.8% | +16.5% |
| 3-Year ReturnCumulative with dividends | -1.5% | +19.7% | -4.2% | +14.5% |
| 5-Year ReturnCumulative with dividends | -1.5% | -69.1% | -27.7% | +60.9% |
| 10-Year ReturnCumulative with dividends | -1.5% | -87.0% | +26.5% | -11.0% |
| CAGR (3Y)Annualised 3-year return | -0.5% | +6.2% | -1.4% | +4.6% |
DBVT leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MDT and ALKS each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than KMTS's 1.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs KMTS's 71.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KMTSKESTRA MEDICAL TE… | DBVTDBV Technologies … | MDTMedtronic plc | ALKSAlkermes plc |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.87x | 1.26x | 0.47x | 1.06x |
| 52-Week HighHighest price in past year | $30.00 | $26.18 | $106.33 | $36.60 |
| 52-Week LowLowest price in past year | $13.25 | $7.53 | $77.16 | $25.17 |
| % of 52W HighCurrent price vs 52-week peak | +71.7% | +76.3% | +73.3% | +96.7% |
| RSI (14)Momentum oscillator 0–100 | 48.1 | 48.1 | 27.3 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 357K | 252K | 7.8M | 2.3M |
Evenly matched — MDT and ALKS each lead in 1 of 2 comparable metrics.
Analyst Outlook
MDT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: KMTS as "Buy", DBVT as "Buy", MDT as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 24.3% for ALKS (target: $44). For income investors, MDT offers the higher dividend yield at 3.57% vs KMTS's 0.16%.
| Metric | KMTSKESTRA MEDICAL TE… | DBVTDBV Technologies … | MDTMedtronic plc | ALKSAlkermes plc |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $28.00 | $46.33 | $109.50 | $44.00 |
| # AnalystsCovering analysts | 4 | 15 | 49 | 28 |
| Dividend YieldAnnual dividend ÷ price | +0.2% | — | +3.6% | — |
| Dividend StreakConsecutive years of raises | 5 | 0 | 36 | 0 |
| Dividend / ShareAnnual DPS | $0.03 | — | $2.78 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +3.2% | +0.5% |
MDT leads this category, winning 2 of 2 comparable metrics.
Key Takeaway
MDT leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). ALKS leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallMedtronic plc (MDT)Leads 2 of 6 categories
Loading custom metrics...
KMTS vs DBVT vs MDT vs ALKS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is KMTS or DBVT or MDT or ALKS a better buy right now?
For growth investors, KESTRA MEDICAL TECHNOLOGIES, LTD.
(KMTS) is the stronger pick with 115. 1% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — KMTS or DBVT or MDT or ALKS?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
6x versus Alkermes plc at 24. 8x.
03Which is the better long-term investment — KMTS or DBVT or MDT or ALKS?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: MDT returned +26. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — KMTS or DBVT or MDT or ALKS?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
47β versus KESTRA MEDICAL TECHNOLOGIES, LTD. 's 1. 87β — meaning KMTS is approximately 302% more volatile than MDT relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 59% for Medtronic plc — giving it more financial flexibility in a downturn.
05Which is growing faster — KMTS or DBVT or MDT or ALKS?
By revenue growth (latest reported year), KESTRA MEDICAL TECHNOLOGIES, LTD.
(KMTS) is pulling ahead at 115. 1% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Medtronic plc grew EPS 30. 8% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — KMTS or DBVT or MDT or ALKS?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -190. 3% for KESTRA MEDICAL TECHNOLOGIES, LTD. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDT leads at 17. 8% versus -177. 8% for KMTS. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is KMTS or DBVT or MDT or ALKS more undervalued right now?
Analyst consensus price targets imply the most upside for DBVT: 131.
8% to $46. 33.
08Which pays a better dividend — KMTS or DBVT or MDT or ALKS?
In this comparison, MDT (3.
6% yield), KMTS (0. 2% yield) pay a dividend. DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is KMTS or DBVT or MDT or ALKS better for a retirement portfolio?
For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
47), 3. 6% yield). KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) carries a higher beta of 1. 87 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +26. 5%, KMTS: -1. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between KMTS and DBVT and MDT and ALKS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: KMTS is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; MDT is a mid-cap income-oriented stock; ALKS is a small-cap quality compounder stock. MDT pays a dividend while KMTS, DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.